Seaport Therapeutics, Inc. - 10-Q Filing
Seaport Therapeutics reports Q3 2026 financial results featuring ongoing R&D expenditures for Glyph and Monash license agreements.
Tickers: $SPTX
Seaport Therapeutics reports Q3 2026 financial results featuring ongoing R&D expenditures for Glyph and Monash license agreements.
Tickers: $SPTX